4564 — OncoTherapy Science Balance Sheet
0.000.00%
- ¥6bn
- ¥5bn
- ¥610m
Annual balance sheet for OncoTherapy Science, fiscal year end - March 31st, JPY millions except per share, conversion factor applied.
2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | Yuho | Yuho | Yuho | Yuho | Yuho |
Standards: | JAS | JAS | JAS | JAS | JAS |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Cash and Short Term Investments | 4,714 | 2,899 | 1,837 | 1,118 | 528 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 29.2 | 152 | 400 | 123 | 189 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 4,878 | 3,194 | 2,601 | 1,422 | 818 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 113 | 94.9 | 0.017 | 0 | 0 |
Net Intangible Assets | |||||
Other Long Term Assets | |||||
Total Assets | 5,088 | 3,368 | 2,685 | 1,511 | 867 |
Notes Payable / Short Term Debt | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 243 | 195 | 605 | 609 | 360 |
Long Term Debt | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Total Other Liabilities | |||||
Total Liabilities | 360 | 291 | 705 | 656 | 514 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
Other Equity | |||||
Total Equity | 4,728 | 3,077 | 1,980 | 855 | 354 |
Total Liabilities & Shareholders' Equity | 5,088 | 3,368 | 2,685 | 1,511 | 867 |
Total Common Shares Outstanding |